BioMarin initiated at Oppenheimer

BioMarin initiated with a Perform at Oppenheimer. Oppenheimer analyst Leland Gershell started BioMarin Pharmaceutical with a Perform rating and $92 price target. The analyst sees the shares as range-bound given lack of clarity on the company’s future growth prospects. Further, Gershell notes BioMarin’s “high peer-relative” enterprise value to revenue multiple.
https://thefly.com/landingPageNews.php?id=2836989